Of this budget, 60.3 billion will come from MEXT, 47.5 billion from MHLW, and 18.3 billion from METI. The research-related share of the expenditures is 77.7 billion Yen, with a focus on intractable disease research, the initiative on rare and undiagnosed diseases (IRUD initiative) and on creating business seeds. Following consultations, AMED will also modify some of her targets for key performance indicators.

Nikkei Biotech, January 19 and 25, 2017